Could a common diabetes drug help transplanted kidneys survive longer?
NCT ID NCT07555106
First seen May 07, 2026 · Last updated Jun 24, 2026 · Updated 6 times
Summary
This study tests whether dapagliflozin, a drug usually used for diabetes, can improve kidney function in people who have received a kidney from a living donor. Fifty-four adult transplant recipients will take either dapagliflozin or standard care for 12 months. Researchers will measure changes in kidney function, scarring, and overall health to see if the drug offers extra protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Universidad de Guadalajara
Guadalajara, Jalisco, 44250, Mexico
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (a diabetes drug that may also protect the kidneys)
What this could lead to
If it works, this could point toward a way to help transplanted kidneys last longer and work better.
What could go wrong
This is a small, early-phase trial with only 54 people, so results may not apply to everyone. The drug could also increase the risk of infections or other side effects in transplant patients.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.